While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

Almac Clinical Technologies is a global provider of Interactive Response Technology (IRT) and expert consultancy for the biopharmaceutical industry, empowering trial sponsors to pro-actively manage ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...

The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...